Literature DB >> 28526963

Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.

Rachel H Rose1, David B Turner2, Sibylle Neuhoff2, Masoud Jamei2.   

Abstract

Following a meal, a transient increase in splanchnic blood flow occurs that can result in increased exposure to orally administered high-extraction drugs. Typically, physiologically based pharmacokinetic (PBPK) models have incorporated this increase in blood flow as a time-invariant fed/fasted ratio, but this approach is unable to explain the extent of increased drug exposure. A model for the time-varying increase in splanchnic blood flow following a moderate- to high-calorie meal (TV-Q Splanch) was developed to describe the observed data for healthy individuals. This was integrated within a PBPK model and used to predict the contribution of increased splanchnic blood flow to the observed food effect for two orally administered high-extraction drugs, propranolol and ibrutinib. The model predicted geometric mean fed/fasted AUC and C max ratios of 1.24 and 1.29 for propranolol, which were within the range of published values (within 1.0-1.8-fold of values from eight clinical studies). For ibrutinib, the predicted geometric mean fed/fasted AUC and C max ratios were 2.0 and 1.84, respectively, which was within 1.1-fold of the reported fed/fasted AUC ratio but underestimated the reported C max ratio by up to 1.9-fold. For both drugs, the interindividual variability in fed/fasted AUC and C max ratios was underpredicted. This suggests that the postprandial change in splanchnic blood flow is a major mechanism of the food effect for propranolol and ibrutinib but is insufficient to fully explain the observations. The proposed model is anticipated to improve the prediction of food effect for high-extraction drugs, but should be considered with other mechanisms.

Entities:  

Keywords:  PBPK; food effect; high extraction ratio; pharmacokinetics; splanchnic blood flow

Mesh:

Year:  2017        PMID: 28526963     DOI: 10.1208/s12248-017-0099-z

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  73 in total

1.  Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.

Authors:  E M Howgate; K Rowland Yeo; N J Proctor; G T Tucker; A Rostami-Hodjegan
Journal:  Xenobiotica       Date:  2006-06       Impact factor: 1.908

2.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

3.  Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation.

Authors:  H Liedholm; A Melander
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

4.  Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol.

Authors:  C G Regårdh; G Johnsson; L Jordö; P Lungborg; B A Persson; O Rönn
Journal:  J Cardiovasc Pharmacol       Date:  1980 Nov-Dec       Impact factor: 3.105

5.  Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10.

Authors:  Taina Sten; Saana Qvisen; Päivi Uutela; Leena Luukkanen; Risto Kostiainen; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2006-06-08       Impact factor: 3.922

6.  Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.

Authors:  K M Sowinski; B S Burlew
Journal:  Pharmacotherapy       Date:  1997 Nov-Dec       Impact factor: 4.705

7.  Superior mesenteric artery blood flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals.

Authors:  M B Sidery; I A Macdonald; P E Blackshaw
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

8.  Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.

Authors:  I H Benedek; W D Fiske; W O Griffen; R M Bell; R A Blouin; P J McNamara
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

9.  Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7.

Authors:  Nobumitsu Hanioka; Keiko Hayashi; Takeshi Shimizudani; Kenjiro Nagaoka; Akiko Koeda; Shinsaku Naito; Shizuo Narimatsu
Journal:  Pharmacology       Date:  2008-10-21       Impact factor: 2.547

10.  Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.

Authors:  Nikunjkumar Patel; Sebastian Polak; Masoud Jamei; Amin Rostami-Hodjegan; David B Turner
Journal:  Eur J Pharm Sci       Date:  2013-09-21       Impact factor: 4.384

View more
  7 in total

Review 1.  Physiological parameter values for physiologically based pharmacokinetic models in food-producing animals. Part I: Cattle and swine.

Authors:  Zhoumeng Lin; Miao Li; Yu-Shin Wang; Lisa A Tell; Ronald E Baynes; Jennifer L Davis; Thomas W Vickroy; Jim E Riviere
Journal:  J Vet Pharmacol Ther       Date:  2020-04-08       Impact factor: 1.786

Review 2.  Predictive Performance of Physiologically Based Pharmacokinetic Models for the Effect of Food on Oral Drug Absorption: Current Status.

Authors:  Mengyao Li; Ping Zhao; Yuzhuo Pan; Christian Wagner
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-11-23

3.  Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.

Authors:  Muhammad Nasir Kalam; Muhammad Fawad Rasool; Faleh Alqahtani; Imran Imran; Asim Ur Rehman; Naveed Ahmed
Journal:  Drug Des Devel Ther       Date:  2021-03-17       Impact factor: 4.162

4.  PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease.

Authors:  Maiara Camotti Montanha; Nicolas Cottura; Michael Booth; Daryl Hodge; Fazila Bunglawala; Hannah Kinvig; Sandra Grañana-Castillo; Andrew Lloyd; Saye Khoo; Marco Siccardi
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

5.  Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.

Authors:  Sarah Alrubia; Jialin Mao; Yuan Chen; Jill Barber; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2022-09-03       Impact factor: 5.577

6.  Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans.

Authors:  Benjamin Guiastrennec; David P Sonne; Martin Bergstrand; Tina Vilsbøll; Filip K Knop; Mats O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-08-12

7.  Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV.

Authors:  Ahizechukwu C Eke; Adeniyi Olagunju; Brookie M Best; Mark Mirochnick; Jeremiah D Momper; Elaine Abrams; Martina Penazzato; Tim R Cressey; Angela Colbers
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.